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MRI Visualization of Melanoma Cells by Targeting Overexpressed Sialic 
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Simonetta Geninatti Crich*, Diego Alberti, Ibolya Szabo, Silvio Aime, Kristina Djanashvili* 
Altered glycosylation of cell surface proteins and lipids is frequently 
associated with tumorigenic and metastatic processes.[1] These 
changes in glycosylation are mainly caused by an increased 
expression of sialyltransferases, which glycosylate exposed glycans 
at their terminal positions with anionic monosaccharide sialic acid 
residues (Sia). Tumor cells overexpressing Sia appear protected to 
the immune defense system, and as a result, malignancy is 
increased.[2] Numerous studies have demonstrated that Sia are 
relevant biomarkers of metastatic activity of tumors,[3] and that Sia 
expression on cancer cells correlates with the prognosis of 
patients.[4] Currently the determination of the sialylation status of 
solid tumors is carried out on tissue sections from biopsies. This is 
not only an invasive procedure, it also bears an intrinsic risk that the 
sample is not representative for the whole, potentially heterogeneous 
tumor. Therefore, we have investigated probes that are able to non-
invasively visualize Sia in vivo.  
Macrocyclic or linear lanthanide complexes appear interesting 
candidates for this intended application, because they can be used 
either as contrast agents (CA) for magnetic resonance imaging 
(MRI) or as radiopharmaceuticals for imaging and therapy of tumors. 
For both tasks, accurate delivery and retention of the complex at the 
site of disease is mandatory. Previously, we have demonstrated the 
affinity of 160Tb-DTPA-bisamide (DTPA = diethylenetriamine 
pentaacetic acid) conjugated to a phenylboronic acid (PBA) moiety 
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Figure 1. Schematic representation of sialic acid recognition by 
imaging reporter Gd(III)-DOTA-EN-PBA via diol-phenylboronic 
interaction on the surface of tumor cells.  
is based on the reversible formation of five- and six-membered 
cyclic boronate esters between PBA and the exocyclic polyol 
function of Sia[6] (Scheme 1). Although this type of binding has 
extensively been exploited for the design of various saccharide 
sensors[7] and Sia determination assays,[8] its application for in vivo 
targeting of tumors has not yet been reported. Here, for the first time, 
we demonstrate in vivo visualization of tumors via the highly 
selective dynamic covalent binding between the diol-function of 
overexpressed Sia and a PBA-targeting vector conjugated with an 
MRI reporter (Figure 1). 
The DOTA chelate (DOTA = 1,4,7,10-tetraazacyclododecane 
1,4,7,10-tetraacetate) has been chosen for the design of the targeting 
imaging reporter DOTA-EN-PBA due to the superior kinetic 
stability of its complexes with Ln(III) ions compared to previously 
reported DTPA-bisamide-PBA-complexes[5,9] Conjugation of the 
PBA-function was carried out via the ethylenediamine (EN) spacer. 
The aminogroup of DOTA-EN-PBA, being positively charged at 
physiological pH, facilitates the recognition mechanism through the 
electrostatic affinity to the negatively charged carboxylic groups of 
the Sia residues. The role of this auxiliary interaction has been 
supported previously by a computer modeling study.[5a] 
Since Sia expression is directly correlated to melanogenesis, the 
recognition ability of the designed complex has been evaluated on 
murine melanoma B16-F10 cells. This cell line is commonly used as 
a well-characterized, highly proliferative tumor model. In melanoma 
cells, the activity of tyrosinase, the key enzyme for melanogenesis, 
shows a good correlation with intra- and extracellular Sia levels.[10] 
This indicates an essential role of Sia residues in the enzyme 
expression and, therefore, in melanoma cells differentiation. 
Sialylation/desialylation of some relevant molecules, such as 
melanosomal sialo-glycoconjugates and tyrosinase itself, participate 
in the regulation of expression of melanogenic functions. For these 
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reasons, two clones of B16-F10 murine melanoma characterized by 
a different phenotype, namely melanogenic (B16-F10m) and non-
melanogenic (B16-F10non-m) cells, have been used to test the PBA-
based imaging reporter in vitro. The two phenotypes have been 
obtained by growing cells at different pH values. In fact, it is known 
that B16-F10 cells only form melanin when they are maintained in 
culture at pH 7.2–7.4.[11] At lower pH melanogenesis is inhibited 
whereas other metabolic processes remain almost unaffected. The 
level of Sia in the B16-F10m clone has been determined to be 3.6 
times higher compared to B16-F10non-m, which is in accordance with 
the reported values.[11] The specific binding of Gd(III)-DOTA-EN-
PBA to the tumor cells overexpressing Sia was assessed by 
relaxation rates measurements on the washed cell pellets after 
incubation with a 0.6 mM solution of the complex for 4 hours at 37 ºC. 
Table 1. Response of melanogenic and non-melanogenic cells to the 
incubation with Gd(III)-DOTA-EN-PBA (0.6 mM, 4h, 37 ºC). 
[a] determined by ICP-MS; [b] determined by AbCAM assay. The data represent 
the results obtained on the basis of five independent experiments.  
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Figure 2. Correlation between sialic acid expression and relaxation 
rates (R2 = 0.9329) measured on cells incubated with Gd(III)-DOTA-


























Figure 3. Gd-content measured by ICP-MS after incubation of B16-
F10m (grey solid bar) and B16-F10non-m (white solid bar) cells with 
Gd(III)-DOTA-EN-PBA with or without pre-incubation with theophylline 
(dashed bars). Error bars have been calculated on the basis of three 
replicate experiments. Student’s t-test was used to compare the 
differences between Gd content before and after theophylline addition.  
B16-F10m: P = 0.0015; B16-F10non-m: P < 0.0001. A P value < 0.05 
has been considered statistically significant. 
From the results reported in Table 1 it is evident that there is a 
marked accumulation of the complex at the melanogenic cells that 
yields high relaxation rates (R1=1/T1), as a result of a higher Gd-
content, as confirmed by ICP-MS measurements. The relaxation 
rates are in good correlation with the Sia expression (Figure 2). 
In order to get further insights into the relationship between 
Gd(III)-DOTA-EN-PBA uptake and the sialylation level/ 
melanogenic activity, B16-F10 cells have been incubated for 24 
hours with a 0.9 mM solution of theophylline, a well-known 
pigmentation enhancer in murine melanoma cells.[11] As an inhibitor 
of phosphodiesterase, theophylline has been shown to extensively 
stimulate pigment production and tyrosinase activity of melanoma 
cells in vitro. As expected, expression of Sia by the cells pre-
incubated with theophylline increased significantly, resulting in 
accumulation of larger quantities of the Gd-complex (Figure 3). This 
increased binding effect is especially remarkable for the non-
melanogenic cells, which is 7 times higher compared to the 
melanogenic cell, resulting in a similar level of Sia expression for 
both cell types. The differences in the Gd-levels, measured in this 
experiment compared to the one reported in Table 1 can be 
explained by the variability of the Sia-expression by the B16-F10 
cells depending on the conditions, i.e. pH, composition of medium, 
number of passages after cell de-freezing etc. 
It is reasonable to assume that successful in vivo tumor targeting, 
based on the recognition of Sia residues by a PBA-vector, could be 
hampered by its competitive binding to glucose in blood (typically 
present in between 3.5 and 5.8 mM concentration). The formation of 
cyclic esters of PBA and glucose is well documented,[12] and 
therefore, the interaction of Gd(III)-DOTA-EN-PBA with B16-F10m 
cells was evaluated at different concentrations in the presence (5.8 
mM) or in the absence of glucose. In both cases, the cells were 
incubated for 4h with the complex after which the incubation 
medium was removed, the cells were washed, detached with EDTA, 
and the water proton relaxation rates of cell suspensions were 
measured.  



















Figure 4. (A) Relaxation rates measured for B16-F10 murine melanoma cells, 
incubated for 4 hours at 37 ºC, with various concentrations of Gd(III)-DOTA-EN-
PBA in the presence (circles) or the absence (squares) of glucose (5.8 mM), 
detachment by EDTA has been applied; The continuous line is the result of the 
fitting of the data by the equations described in the supporting information 
session   . (B) T1-weighted spin-echo MR images of agar phantoms containing: 
Cell type R1obs (s-1) [Gd] (mol/mg 
protein)[a] 
[Sia] (mol/mg  
protein) [b] 
B16-F10m 0.74 ± 0.03 1.50 (± 0.5)  10-9 7.3 (± 0.6)  10-9 
B16-F10non-m 0.51 ± 0.04 0.20 (± 0.5)  10-9 1.5 (± 0.4)  10-9 
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Figure 5. Fat-suppressed T1-weighted MR spin-echo images of C57BL/6 mice grafted subcutaneously with B16-F10 melanoma cells recorded 
at 7T (A) before and (B) 4h after the administration of Gd(III)-DOTA-EN-PBA. For comparison, the analogues measurements were performed 
(C) before and (D) 4h after the administration of Gd-HPDO3A. The corresponding MRI % SI enhancements (E) were measured in melanoma 
tumors and muscle 4 and 24h after the injection of Gd(III)-DOTA-EN-PBA; the data obtained after injection of Gd(III)-HPDO3A is reported in the 
Supporting Information (Figure S1). (F) A plot of MRI % SI enhancements measured in melanoma tumors and muscle with or without the PRE-
injection with a high dose (0.15mmol/kg) of Eu(III)-DOTA-EN-PBA  
As expected, a moderate decrease of relaxation rates as a result of 
the competitive binding between the complex and glucose in the 
medium has been observed. However, when the incubation is 
performed using Gd(III)-DOTA-EN-PBA > 1mM, the competition 
effect is negligible. At these concentrations the amount of the free  
(not bound to glucose) complex is high enough to saturate all Sia-
residues available on the cell surface as demonstrated by the 
saturating behavior of the curve. This observation can be 
rationalized by the lower affinity of PBA to glucose compared to 
Sia.[13] This is due to the fact that D(+)glucose is present in solution 
predominantly (>99%) in its pyranose anomeric form. In this 
configuration, the diol-groups are in an unfavorable position for the 
formation of PBA-esters compared to those of Sia, positioned on a 
flexible glycerol tail.[6] The analysis of the relaxation rate behavior 
in the absence of glucose as a function of the concentration of 
Gd(III)-DOTA-EN-PBA and the equilibria involved are discussed in 
the Supporting Information. The same minor effect of glucose 
present in the medium on probe uptake by cells is demonstrated by 
MRI images of both melanoma clones (Figure 4B). Melanogenic 
cells (capillaries 2,3) expressing high levels of Sia on their surfaces 
appear hyperintense on T1-weighted images compared to non-
melanogenic cells (capillaries 5,6). When cells were incubated with 
probe in the presence (capillaries 3,6) or in the absence (capillaries 
2,4) of glucose, suspensions containing the same type of cells are 
almost isointense on the images demonstrated only a minor 
influence of glucose on the binding of Gd(III)-DOTA-EN-PBA to 
the cells.  
Next, in vivo MRI experiments were carried out on mice models 
bearing a tumor xenograft obtained by subcutaneous injection of ca. 
1  106 B16-F10m cells on the right flank. After 8 - 10 days, the 
tumor volume was between 20 and 40 mm3, i.e. well detectable by 
MRI. Five animals were then intravenously administered with 0.1 
mmol/kg of Gd(III)-DOTA-EN-PBA. A second group of mice (n = 
5) received the same dose of Gd-HPDO3A (a commercial MRI 
agent with unspecific vascular and extravascular distribution) as 
control. Fat-suppressed T1-weighted multislice multiecho MR 
images were recorded before, 4 and 24 hours after the contrast agent 
administration (Figure 5). The analysis of Signal Intensity (SI) % 
enhancement measured on the ROI drawn on the whole tumor 
regions, was of 25% and 10% at 4 and 24 hours after the injection of 
the targeting probe, respectively, while no persistent SI was 
observed for animals injected with the control probe (Supporting 
Information, Figure S1). From the image 5B, it is apparent that the 
probe can visualize the heterogeneity of tumor. The % SI 
enhancement recorded on mice treated with Gd-HPDO3A at the 
same Gd dose (Figure 5C and E) was markedly lower and without 
any significant difference between muscle and tumor regions. Then, 
in order to demonstrate the tumor cell binding specificity of Gd(III)-
DOTA-EN-PBA, a competition experiment has been performed 
with Eu(III)-DOTA-EN-PBA (0.15mmol/kg) that does not influence 
the SI in T1-weighted MR images. Briefly, a group of four mice has 
been treated with 0.15mmol/kg of Eu(III)-DOTAENPBA and after 
3h with 0.1mmol/kg of Gd(III)-DOTAENPBA. Figure 5F shows 
that % SI enhancements measured 4h after the Gd-complex injection 
on the ROI drawn on the whole tumor regions were significantly 
lower than those measured in the absence of the competitor, thus 
supporting the view of Gd(III)-DOTA-EN-PBA binding specificity. 
In conclusion, we have demonstrated for the first time the 
feasibility of in vivo tumor targeting based on the recognition of 
overexpressed sialic acid by a PBA-based imaging reporter. The 
herein reported results on murine melanoma tumor may be likely 
extended to other tumor types, such as breast cancer, known to 
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exhibit high levels of Sia[1] as a function of their metastatic potential. 
The high expression of Sia on the cell surface (ca. 1  109/cell) 
permits their MRI visualization both in vitro and in vivo using a low 
molecular weight Gd-complex. The use of small-sized targeting 
contrast agents has evident advantages compared to the use of 
targeting nanoparticles in terms of their i) stability, ii) access to the 
cellular targets or iii) general toxicity issues. This proof of concept 
opens new avenues for the design of tumor-specific imaging probes. 
The prolonged retention of Gd(III)-DOTA-EN-PBA at the tumor 
site after injection suggests the possibility of using this probe for 
therapy, provided that a suitable radionuclide is used for labeling of 
the DOTA-EN-PBA ligand. Research along these lines is currently 
under our close attention. 
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Materials and Methods 
All chemicals, purchased from Sigma-Aldrich were of analytical grade and where used without further 
purification. DOTA-EN-PBA was synthesized according to a procedure reported previously,[1] and 
optimized as given below. All the reactions were monitored by TLC on silica plates detecting the 
components by UV light or by applying the Dragendorff reagent. NMR spectroscopy was performed on 
Varian Inova-300 spectrometer, operating at 300, 75 and 96 MHz for 1H, 75C and 11B, respectively.  
Longitudinal water proton relaxation rate was measured on a Stelar Spinmaster spectrometer (Stelar, Mede, 
Italy) operating at 20 MHz, by means of the standard inversion-recovery technique (16 experiments, 2 
scans). A typical 90° pulse width was 3.5 ms, and the reproducibility of the T1 data was < 0.5%. 
Cell Lines 
Mouse melanoma (B16-F10) cell lines were purchased from the American Type Culture Corporation. 
Melanogenic B16-F10m cells were obtained by growing cells in standard DMEM (Lonza) medium 
supplemented with sodium bicarbonate, and glutamine. The cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO2. Non-melanogenic B16-F10non-m cells were obtained by growing B16-F10 in 
RPMI (Lonza) containing sodium bicarbonate and glutamine. The cells were incubated at 37 °C in a 
humidified atmosphere of 10% CO2. Both media were supplemented with 10% (v/v) FBS, 2 mM 
glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin.  Melanogenesis was evaluated by measuring 
the absorbance of cell lysate and medium (dissolved in NaOH 1M) at 490 nm observing its linear 
dependency on the number of cell passages. The Sia expression on B16-F10 cells was determined using a 





































































Scheme S1. Synthetic route for the preparation of Gd(III)-DOTA-EN-PBA. 
 
Tris-1,4,7-tert-butoxycarbonylmethyl-10-ethoxycarbonyl-1,4,7,10-tetraaza- cyclododecane (2): Solid 
K2CO3 (3.15 g, 22.77 mmol) was added to a solution of the HBr salt of tris-1,4,7-tert-
butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane (1) (2.03 g, 3.36 mmol) in 28 mL of acetonitrile, 
and then the mixture was stirred for 1 h at room temperature. The suspension was cooled down to 0 ºC in 
an ice-water bath and a solution of ethyl bromoacetate (0.63 g, 3.78 mmol) in 5 mL of acetonitrile was 
added dropwise over 15 min. The reaction mixture was stirred overnight at ambient temperature. The 
suspended salts were removed by filtration and the solvent was evaporated under reduced pressure. After 
purification of the residue by column chromatography (silica, CH2Cl2/MeOH gradient from 95:5 to 
80:20) 2.63 g (88%) of 2 were obtained.  
1H NMR (CDCl3, 25 ºC, TMS): δ = 1.16 (t, J = 7.2 Hz, 3H), 1.45 (s, 18H), 1.47 (s, 9H), 1.80–3.80 (broad 
multiplets, 24H), 4.17 (q, J = 7.2 Hz, 2H). 13C NMR (CDCl3, 25 ºC, TMS): δ  = 14.14, 30.95, 27.91, 
28.02, 51.96, 53.50, 54.71, 54.91, 55.67, 55.73, 62.26, 82.08, 82.16, 172.92, 173.02, 173.60. 
Monoamide of ethylendiamine and tris-1,4,7-tert-butoxycarbonylmethyl-10-carboxymethyl-
1,4,7,10-tetraazacyclododecane (3): This compound was prepared and characterized according to a 
published procedure[2] in 72% yield (1.53 g). 
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Conjugate of 3 and 3-formylphenylboronic acid (4): To a solution of 3 (1.34 g, 2.18 mmol) in 15 mL 
of methanol, 3-formylphenylboronic acid (0.35 g, 2.39 mmol) was added. After addition of 5 mL of 
freshly distilled triethylamine, the reaction mixture was stirred for 2 h at room temperature. After the 
conversion of the amine to the imine (followed by NMR), NaBH4 (139 g, 26.41 mmol) was carefully 
added to the reaction mixture. The resulting solution was stirred at room temperature for 12 h. The 
solvent was removed under reduced pressure to give a brownish foam. The residue was taken up in water 
and the resulting mixture was extracted three times with dichloromethane. After evaporation of the 
combined organic phases, 1.56 g of compound 4 (97%) were obtained, which was used in the next 
reaction step without further purification. 
Deprotection of 4. A solution containing 4 (2.34 g, 3.13 mmol) in 5 mL CH2Cl2/TFA (3:1) was stirred 
overnight. The solvent was removed under reduced pressure; the residue was taken up in methanol 
several times, which was removed each time by evaporation, until a light yellow foam was formed. The 
final residue was dissolved in water and the pH was adjusted to 12. This basic solution was brought on 
the ion exchange column and rinsed with water until the pH of the eluent was neutral. The final product 
was eluted with a mixture of pyridine (10% in water)/ethanol (1:1). The fractions obtained were analyzed 
by TLC. Lyophilization of the purified material gave 615 mg (1.06 mmol, 33%) of 5.  
1H NMR (D2O, 25 °C, pH 12, internal reference t-BuOH at 1.20 ppm): δ = 2.78–3.48 (m, 20H), 3.68–
3.71 (m, 8H), 4.70 (s, 2H), 7.49–7.73 (m, 4H).  
13C NMR (75 MHz, D2O, 25 °C, pH 12, internal reference t-BuOH at 31.20 ppm): δ = 35.98, 46.59, 
48.66, 48.94, 50.64, 51.04, 51.23, 52.23, 56.70, 57.12, 128.96, 130.60, 132.66, 134.91, 135.42, 137.85, 
169.81, 173.06, 178.46.  
11B NMR (D2O, 25 °C, pH 12, external reference 0.1M H3BO3 at 0 ppm): δ = –16.79.  
The complexation of the ligand with Gd(III)-ion was performed by the dropwise addition of an aqueous 
solution of GdCl3 to an aqueous solution of DOTA-EN-PBA (5% excess). The mixture was stirred at 50 
ºC for 24 hours, and the pH was adjusted to 7.4 using a 1M solution of NaOH, and maintained constant 
until no changes due to the complexation were observed. The final Gd(III)-DOTA-EN-PBA complex was 
obtained as a white powder after lyphilization. The formation of the complex was identified by ESI-MS: 
m/z = 735.30. The absence of free Gd(III) ion was confirmed by a xylenol orange test.[2] 
[1] K. Djanashvili, T. L. M. ten Hagen, R. Blangé, D. Schipper, J. A. Peters, G. A. Koning, Bioorg. 
Med. Chem. 2011, 19, 1123-1130. 
[2] J. P. André, C. F. G. C. Geraldes, J. A.  Martins, A. E.  Merbach, M. I. M.  Prata, A. C. Santos, 
J.J.P. de Lima, E. Tóth. Chem. Eur. J. 2004, 10, 5804. 
[3]      A. Barge, G. Gravoto, E. Gianolio, F. Fedelil. Contrast Med. Mol. Imaging. 2006, 1, 184. 
MRI 
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MR images were acquired on a Bruker Avance 300 spectrometer (7T) equipped with a Micro 2.5 
microimaging probe. The system is equipped with two birdcage resonators with 30 and 10mm inner 
diameter, respectively. Glass capillaries containing about 2x106 cells were placed in an agar phantom and 
MR imaging was performed by using a standard T1-weighted multislice spin-echo sequence 
(TR/TE/NEX=200/3.3/8, Matrix size = 128 x 128, FOV = field of view:  FOV = 1.2 cm (cell images, 
FOV = 2.8 cm (mice images), NEX = number of excitations).  
The T1 relaxation times were calculated using a standard saturation recovery spin echo. For in vivo MRI, 
the animals were anesthetized before examination by injecting tiletamine/zolazepam (20 mg/kg; Zoletil 
100, Virbac, Milan, Italy) and xylazine (5 mg/kg; Rompun, Bayer, Milan, Italy). Mice of group 1 (n = 4) 
received intravenously 0.1 mmol/kg of Gd(III)-DOTA-EN-PBA, and mice of group 2 (n = 4) received the 
same amount of Gd-HPDO3A (Prophance, Bracco, Italy). MR images were acquired before 4, and 24 h 
after the contrast agent administration using a T1-weighted, fat-suppressed, multislice protocol 
(TR/TE/NEX 250/3.2/6, 1 slice, 1 mm). Fat suppression was performed by applying a pre-saturation 
pulse (90° BW = 1400 Hz) at the absorption frequency of fat (-1100 Hz from water). The mean signal 
intensity (SI) values were calculated in the regions of interest (ROI) manually drawn on the whole tumor. 
The measured SI was normalized to a standard Gd(III) solution to take into account differences in the 
absolute SI values among different images obtained after mouse repositioning in the MRI scanners. The 
normalization was carried out by dividing the SI0 values of the ROI drawn on the tumor to the SI values 
of the ROI drawn inside the reference tube (SIref): 
SI normalized (SIn)= SI0/SIref                                
The mean measured SI was normalized by using a standard solution of Gd in 1% HNO3. The mean SI 
enhancement (%) of target tissues (TT) was calculated according to the following equation:  
SI % Enhancement = ((mean SI (TT) post-contrast) – (mean SIn (TT) pre contrast))/(mean SIn (TT) pre-
contrast) x 100. 
Tumor region has been defined from T2 weighted RARE images recorded before the acquisition of each 
T1-weighted spin-echo image.  As a consequence of their longer T2, tumors appear hyperintense with 
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respect normal tissues. Due to the long time analysis (up to 24 hours) the reposition the animals was 
unavoidable, making it impossible to compare images slice by slice. Therefore, the SI enhancement has 
been calculated on the whole tumor by averaging SI enhancement measured on each slice.    
 
Analysis of the relaxation rate behavior (Figure 4A) measured in the absence of glucose as function 
of Gd(III)-DOTA-EN-PBA concentration. 
The following equilibria have been considered for the analysis: 
[Gd-DOTA-EN-PBA] + [Sia] ↔  [Gd-DOTA-EN-PBA@Sia] 
Ka = [Gd-DOTA-EN-PBA@Sia] / ([Sia]f x [Gd-DOTA-EN-PBA]f 
[Gd-DOTA-EN-PBA]tot = [Gd-DOTA-EN-PBA@Sia] + [Gd-DOTA-EN-PBA]f 
Where,  [Sia]t = Sialic acid concentration on B16-F10 cells determined by AbCAM assay 
[Gd-DOTA-EN-PBA]tot = the total amount of complex added to the cell media 
[Gd-DOTA-EN-PBA]f  = the free complex concentration. 
[Sia]t = [Gd-DOTA-EN-PBA@Sia] + [Sia]f 
R1obs = observed relaxation rate measured on cell pellets after incubation with increasing complex 
concentrations.  
R1d  = Diamagnetic contribution to the observed relaxation rate measured on untreated cells without 
incubation with Gd- DOTA-EN-PBA.  
Using equation  R1obs= R1d+r1pb x [Gd-DOTA-EN-PBA@Sia] it was possible to estimate an association constant of 
3700 M-1 and an r1pb of 4 mM-1s-1 (at 7T).  
 
Table S1. Signal intensity enhancement (%) measured on kidneys, liver and spleen 4 and 24h after injection of Gd-
complexes.[a] 
 
Gd-complex/time Kidneys Liver Spleen 
Gd-DOTA-EN-PBA/4h 39 ± 10 5 ± 3 2 ± 1 
Gd-DOTA-EN-PBA/4h 15 ± 3 2 ± 1 0.5 ± 1 
Gd-HPDO3A/4h 31 ± 5 1 ± 1 0.5 ± 1 
Gd-HPDO3A/24h 5 ± 3 1 ± 1 1 ± 1 
[a] The stomach and intestines are highlighted before and after the injection of the contrast agents because the food provided to 
the mice contains paramagnetic ions (such us Fe3+ and Mn2+). The effect of the diet on the appearance of hyperintensity in 
regions of gastrointestinal tract is well known. Only kidneys show a specific enhancement due to the elimination of the Gd-















Figure S1 A plot of MRI SI enhancements (%) measured in melanoma tumors and muscle 4 hours after the 
injection of Gd(III)-HPDO3A. Student’s t-test was used to compare the differences between SI measured in the 




Monitoring of melanogenesis process on B17-F10 cell line 























Figure S2. Cell lysate absorbance dependence on the number of detaching cell passages. Cells lysates were 





























Figure S3. Light microscope photographs (20x) of non-melanogenic (A) and melanogenic (B) B16-F10 cells.  
 
 
    B) 
